` BIO (Bio Rad Laboratories Inc) vs S&P 500 Comparison - Alpha Spread

BIO
vs
S&P 500

Over the past 12 months, BIO has underperformed S&P 500, delivering a return of -15% compared to the S&P 500's 12% growth.

Stocks Performance
BIO vs S&P 500

Loading

Performance Gap
BIO vs S&P 500

Loading
BIO
S&P 500
Difference

Performance By Year
BIO vs S&P 500

Loading
BIO
S&P 500
Add Stock

Competitors Performance
Bio Rad Laboratories Inc vs Peers

S&P 500
BIO
0KHE
TMO
DHR
207940
Add Stock

Bio Rad Laboratories Inc
Glance View

Economic Moat
None
Market Cap
6.9B USD
Industry
Life Sciences Tools & Services

Bio-Rad Laboratories Inc. began its journey in 1952 and has since positioned itself as a formidable player in the life sciences and clinical diagnostics sectors. Founded by David and Alice Schwartz, the company thrived on the burgeoning interest in biological research, carving a niche by supplying essential products to scientists and healthcare professionals. With its headquarters in Hercules, California, Bio-Rad has continually developed a suite of innovative solutions that cater to both academic research and the intricate needs of clinical diagnostics, paving its way to becoming a global leader. Their operations are distinctly bifurcated: Life Science, which focuses on products for gene expression, protein purification, and food safety, and Clinical Diagnostics, offering tools for blood testing and diabetes monitoring. The core of Bio-Rad’s business model lies in its ability to design and manufacture advanced technological products that streamline laboratory processes, making research and diagnostics more efficient and reliable. The Life Science segment generates revenue by selling reagents, lab instruments, and software that facilitate various laboratory protocols and experiments, assisting scientists in their pursuit of breakthroughs in biotechnology and pharmaceutical development. Meanwhile, the Clinical Diagnostics segment garners earnings through the provision of innovative testing and analysis tools that enable accurate disease diagnosis, blood analysis, and quality control. Guided by a robust infrastructure of research and development, the company continuously adapts to the evolving demands of science and healthcare, maintaining its fiscal health while reinforcing its reputation as a trusted provider in the global market.

BIO Intrinsic Value
361.74 USD
Undervaluation 31%
Intrinsic Value
Price
Back to Top